Malaysia has agreed to buy 12.8 million doses of Pfizer’s COVID-19 vaccine, becoming the first country in Southeast Asia to announce a deal with the US drugmaker after some expressed reservations over the need for ultra-cold storage.
While final trial data showed that Pfizer’s vaccine is 95 per cent effective, many Asian countries are not betting on it partly due to tropical heat, remote island communities and a lack of ultra-cold freezers.
Pfizer’s vaccine, jointly developed with German partner BioNTech, must be stored and transported at minus 70 degrees Celsius (-94F), although it can be kept in a fridge for up to five days, or up to 15 days in a thermal shipping box.
Prime Minister Muhyiddin Yassin said on Friday that Malaysia would prioritise “high-risk groups… including frontliners, senior citizens, and those with non-communicable diseases, such as heart diseases and diabetes”.
Pfizer will deliver the first one million doses in the first quarter of 2021, with 1.7 million, 5.8 million and 4.3 million doses to follow in subsequent quarters.
The deal is expected to cover 6.4 million Malaysians, or 20 per cent of the population, with another 10 per cent to be covered under Malaysia’s participation in the global COVAX facility, backed by the World Health Organization.
Malaysia, which will distribute the vaccine to its people for free, reported 1,109 new COVID-19 infections on Friday.
The country is also planning to run a Phase 3 trial of an experimental vaccine developed by the Chinese Academy of Medical Sciences. The trial will involve 3,000 participants.